Increased complement activation is a distinctive feature of severe SARS-CoV-2 infection
This article has been Reviewed by the following groups
Discuss this preprint
Start a discussion What are Sciety discussions?Listed in
- Evaluated articles (ScreenIT)
Abstract
Increased complement activation is observed in COVID-19 compared with non-COVID respiratory illness and is a key marker of organ failure.
Article activity feed
-
-
SciScore for 10.1101/2021.02.22.432177: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement IRB: Study Approval: The Institutional Review Board approved this study at both Washington University School of Medicine (ID#201707160, 201801209, 201808171, 201710220, 201808115, and 201910011, 201904191, 202004091, 202003085) and the Yale School of Medicine independently (IRB 2000027792 and 1401013259). Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Table 2: Resources
Software and Algorithms Sentences Resources Statistical analysis was performed using IBM SPSS Statistics for Macintosh, Version 27.0 (IBM Corp, Armonk, NY), and GraphPad Prism 9 (GraphPad Software, La Jolla, CA) was employed for … SciScore for 10.1101/2021.02.22.432177: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement IRB: Study Approval: The Institutional Review Board approved this study at both Washington University School of Medicine (ID#201707160, 201801209, 201808171, 201710220, 201808115, and 201910011, 201904191, 202004091, 202003085) and the Yale School of Medicine independently (IRB 2000027792 and 1401013259). Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Table 2: Resources
Software and Algorithms Sentences Resources Statistical analysis was performed using IBM SPSS Statistics for Macintosh, Version 27.0 (IBM Corp, Armonk, NY), and GraphPad Prism 9 (GraphPad Software, La Jolla, CA) was employed for generating figures. SPSSsuggested: (SPSS, RRID:SCR_002865)GraphPadsuggested: (GraphPad Prism, RRID:SCR_002798)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:Our findings have several limitations. First, the samples were not simultaneously collected among the COVID-19, influenza, and non-COVID acute respiratory failure groups. However, they were collected in a similar time frame leading up to the SARS-CoV-2 pandemic, and subsequently processed using the same protocol, to minimize any differences in the findings. Second, we did not have levels of SARS-CoV-2 RNA to evaluate how complement activation correlates with viral load in COVID-19. A prior report would suggest that markers of complement activation do not correlate with concurrently measured viral load (Holter et al., 2020). This is possible, given that the patients enrolled in our study are likely presenting in the “hyperinflammatory phase” of the illness, when viral loads may be lower than the initial phase of infection (van Kampen et al., 2021). Third, decision-making in our ICU changed over a period of time; initially, there was a tendency for early intubation. Hence, we also included hospitalization and ICU admission in our data points; and provided data on mortality where applicable, derived from our electronic medical records. Fourth, for certain outcomes, our sample size was such that there were differences in the levels of the markers between the two groups, but they did not always meet statistical significance (e.g., mortality signal in sC5b-9); one explanation is that our study was not specifically powered for that outcome, and additionally, there may be other facto...
Results from TrialIdentifier: We found the following clinical trial numbers in your paper:
Identifier Status Title NCT04369469 Active, not recruiting Efficacy and Safety Study of IV Ravulizumab in Patients With… Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
-
